InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Stock Information for FLUENT Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FLUENT Corp.

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.